Rice lab’s injectable gel feeds steady dose of drugs to tumor cells
An immunotherapy drug embedded in a slow-release hydrogel invented at Rice University in collaboration with the University of Texas Health Science Center at Houston (UTHealth) appears to be highly effective at killing cancer cells.
STINGel combines a new class of immunotherapy drugs called stimulator of interferon gene (STING) agonists with an injectable hydrogel that releases the drug in a steady dose to activate the immune system to kill cancer cells. It was developed by the Rice lab of chemist and bioengineer Jeffrey Hartgerink and Rice alum Simon Young, an assistant professor of oral and maxillofacial surgery at UTHealth.
In clinical trials, immunotherapy drugs have demonstrated strong cancer-fighting abilities. Research has also found that the drugs are flushed quickly from the body, and current trials require multiple injections.
The new research, which is detailed in Biomaterials, showed that slow-release peptide gels could continuously deliver immunotherapy drugs to tumor sites for long periods of time.
Hartgerink is a pioneer in the development of self-assembling multidomain peptide (MDP) hydrogels, which mimic the body’s extracellular matrix to encourage the growth of cells and vascular systems for tissue repair. The hydrogel is injected as a liquid, turns semisolid inside the body and slowly degrades over time.
The hydrogel in the new study is also welcoming to cells, but when the invaders are cancer cells, they’re in for trouble. Immunotherapy drugs known as cyclic dinucleotides (CDNs) await them inside the gel.
Hartgerink, a professor of chemistry and bioengineering, said the concentration of CDN in the hydrogel is important.
“The normal approach to CDN delivery is simple injection, but this leads to very rapid diffusion of the drug throughout the body and reduces its concentration at the site of the tumor to very low levels,” he said. “Using the same amount of CDN, the STINGel approach allows the concentration of CDN near the tumor to remain much higher for long periods of time.”
STINGel was studied both in lab cultures and in vivo. For the in vivo portion, six groups of 10 rodents each were treated with CDN alone, control collagens alone or with CDN, MDP alone or STINGel (CDN plus MDP). Only one in 10 CDN or collagen plus CDN animals survived 105 days, but six of 10 animals treated with STINGel survived. These also proved resistant to further implantation of cancer cells, meaning their immune systems were trained to successfully identify and destroy both the existing cancer and future occurrence of that cancer, Hartgerink said.
The lab tested more common hydrogels but found that they were unable to provide the same controlled release and also failed to provide an additional benefit over CDN treatment seen in clinical trials. “The MDP hydrogel provides a unique environment for the release of CDN that other gels just can’t match,” Hartgerink said.
“The CDN we used in this study is currently in clinical trials,” he said. “We think that our STINGel approach has the potential to significantly broaden the scope of this powerful immunotherapy drug to a larger range of resistant cancers.”
The Latest on: Cancer immunotherapy
via Google News
The Latest on: Cancer immunotherapy
- Immunotherapy Drugs Market is Anticipated to Cross US$ 289.52 Billion by 2024 on April 17, 2019 at 7:00 am
Apr 17, 2019 (Heraldkeeper via COMTEX) -- New York, April 17, 2019: Immunotherapy refers to treatments that stimulate, beautify or suppress the body’s personal immune system. Cancer segment is ... […]
- Iteos advancing adenosine antagonist as cancer immunotherapy in phase I/Ib on April 16, 2019 at 9:18 pm
LONDON - Iteos Therapeutics SA has joined the growing band of companies seeking to reverse tumor immune evasion by blocking the anti-inflammatory effects of adenosine signaling, with dosing of the ... […]
- UCSD patient gets first cancer treatment made from stem cells on April 16, 2019 at 7:58 am
A new form of cancer immunotherapy has been given to a University of California, San Diego Health patient in the first test of immune cells grown from stem cells. The patient, Derek Ruff ... […]
- Dr. Socinski on New Applications of Immunotherapy in NSCLC on April 15, 2019 at 1:38 pm
Mark A. Socinski, MD, executive medical director, AdventHealth Medical Group, discusses new applications for immunotherapy in the treatment of patients with non–small cell lung cancer (NSCLC). In ... […]
- Combining Chemotherapy and Immunotherapy for the Treatment of Triple-Negative Breast Cancer on April 15, 2019 at 8:54 am
Recently, various clinical trials have honed in on the use of immunotherapy to treat triple-negative breast cancer. The results of several such studies were presented at the European Society of ... […]
- Cancer Immunotherapy Market to attain a value of US$124.88 billion by 2024 - TMR on April 15, 2019 at 5:15 am
Albany, NY, Apr 15, 2019 (GLOBE NEWSWIRE via COMTEX) -- Albany, NY, April 15, 2019 (GLOBE NEWSWIRE) -- According to TMR, the global cancer immunotherapy market is estimated to expand at a CAGR of 14.6 ... […]
- Cancer cells use tactics to avoid being recognised by immunotherapy agents on April 14, 2019 at 11:53 pm
Researchers have found that bowel cancer cells have a mechanism by which they can switch off some key molecules on their surfaces and thus escape being recognised and killed by the immunotherapy ... […]
- New Target for Cancer Immunotherapy: Exosomes on April 9, 2019 at 6:08 am
It was once a central tenet of biology that RNA molecules did their work inside the cell. But it’s now clear that RNA molecules are also active outside the cell, with potentially major implications ... […]
- Kidney cancer immunotherapy combo approved for NHS use in England on April 5, 2019 at 11:27 am
A combination of immunotherapy drugs will be made available to NHS patients with advanced and aggressive kidney cancer on the NHS in England. The decision to approve the treatment follows an ... […]
- Cancer Immunotherapy May Run Afoul of Exosomal Checkpoint Proteins on April 5, 2019 at 7:35 am
Checkpoint inhibition, a revolutionary cancer immunotherapy, works only in a minority of patients, and scientists want to know why it is resisted in the majority. At the UC San Francisco (UCSF), ... […]
via Bing News